JP2017537910A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537910A5 JP2017537910A5 JP2017529010A JP2017529010A JP2017537910A5 JP 2017537910 A5 JP2017537910 A5 JP 2017537910A5 JP 2017529010 A JP2017529010 A JP 2017529010A JP 2017529010 A JP2017529010 A JP 2017529010A JP 2017537910 A5 JP2017537910 A5 JP 2017537910A5
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- present
- pharmaceutically acceptable
- liquid formulation
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 43
- 239000012669 liquid formulation Substances 0.000 claims 41
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 28
- 239000000872 buffer Substances 0.000 claims 23
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 18
- 239000002738 chelating agent Substances 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 16
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 14
- 229930006000 Sucrose Natural products 0.000 claims 14
- 150000002016 disaccharides Chemical class 0.000 claims 14
- 239000011780 sodium chloride Substances 0.000 claims 14
- 239000005720 sucrose Substances 0.000 claims 14
- 150000005846 sugar alcohols Chemical class 0.000 claims 14
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 13
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 10
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims 10
- 229960003330 pentetic acid Drugs 0.000 claims 10
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 claims 8
- 235000013923 monosodium glutamate Nutrition 0.000 claims 8
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 7
- 239000007995 HEPES buffer Substances 0.000 claims 7
- 229930195725 Mannitol Natural products 0.000 claims 7
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 7
- 239000007997 Tricine buffer Substances 0.000 claims 7
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 239000000594 mannitol Substances 0.000 claims 7
- 235000010355 mannitol Nutrition 0.000 claims 7
- 229940073490 sodium glutamate Drugs 0.000 claims 5
- JLVSRWOIZZXQAD-UHFFFAOYSA-N 2,3-disulfanylpropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(S)CS JLVSRWOIZZXQAD-UHFFFAOYSA-N 0.000 claims 4
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 claims 4
- 241000700618 Vaccinia virus Species 0.000 claims 4
- ACTRVOBWPAIOHC-UHFFFAOYSA-N succimer Chemical compound OC(=O)C(S)C(S)C(O)=O ACTRVOBWPAIOHC-UHFFFAOYSA-N 0.000 claims 4
- 230000003139 buffering effect Effects 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 230000002458 infectious effect Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000004223 monosodium glutamate Substances 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 229940006190 2,3-dimercapto-1-propanesulfonic acid Drugs 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 2
- 102000000311 Cytosine Deaminase Human genes 0.000 claims 2
- 108010080611 Cytosine Deaminase Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 229930182817 methionine Natural products 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 claims 1
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 claims 1
- LVQFQZZGTZFUNF-UHFFFAOYSA-N 2-hydroxy-3-[4-(2-hydroxy-3-sulfonatopropyl)piperazine-1,4-diium-1-yl]propane-1-sulfonate Chemical compound OS(=O)(=O)CC(O)CN1CCN(CC(O)CS(O)(=O)=O)CC1 LVQFQZZGTZFUNF-UHFFFAOYSA-N 0.000 claims 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 claims 1
- NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 claims 1
- RZQXOGQSPBYUKH-UHFFFAOYSA-N 3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCC(CO)(CO)NCC(O)CS(O)(=O)=O RZQXOGQSPBYUKH-UHFFFAOYSA-N 0.000 claims 1
- XCBLFURAFHFFJF-UHFFFAOYSA-N 3-[bis(2-hydroxyethyl)azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCCN(CCO)CC(O)CS(O)(=O)=O XCBLFURAFHFFJF-UHFFFAOYSA-N 0.000 claims 1
- VTOWJTPBPWTSMK-UHFFFAOYSA-N 4-morpholin-4-ylbutane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCN1CCOCC1 VTOWJTPBPWTSMK-UHFFFAOYSA-N 0.000 claims 1
- 239000007991 ACES buffer Substances 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 108700016232 Arg(2)-Sar(4)- dermorphin (1-4) Proteins 0.000 claims 1
- 239000007992 BES buffer Substances 0.000 claims 1
- 239000007989 BIS-Tris Propane buffer Substances 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 claims 1
- GIZQLVPDAOBAFN-UHFFFAOYSA-N HEPPSO Chemical compound OCCN1CCN(CC(O)CS(O)(=O)=O)CC1 GIZQLVPDAOBAFN-UHFFFAOYSA-N 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 239000007993 MOPS buffer Substances 0.000 claims 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- DBXNUXBLKRLWFA-UHFFFAOYSA-N N-(2-acetamido)-2-aminoethanesulfonic acid Chemical compound NC(=O)CNCCS(O)(=O)=O DBXNUXBLKRLWFA-UHFFFAOYSA-N 0.000 claims 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000700629 Orthopoxvirus Species 0.000 claims 1
- 239000007990 PIPES buffer Substances 0.000 claims 1
- 241000700639 Parapoxvirus Species 0.000 claims 1
- 239000007994 TES buffer Substances 0.000 claims 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 1
- HHKZCCWKTZRCCL-UHFFFAOYSA-N bis-tris propane Chemical compound OCC(CO)(CO)NCCCNC(CO)(CO)CO HHKZCCWKTZRCCL-UHFFFAOYSA-N 0.000 claims 1
- 239000013522 chelant Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14306930 | 2014-12-01 | ||
| EP14306930.0 | 2014-12-01 | ||
| PCT/EP2015/078239 WO2016087457A1 (en) | 2014-12-01 | 2015-12-01 | Stable liquid vaccinia virus formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537910A JP2017537910A (ja) | 2017-12-21 |
| JP2017537910A5 true JP2017537910A5 (enExample) | 2019-01-17 |
| JP6655618B2 JP6655618B2 (ja) | 2020-02-26 |
Family
ID=52002884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529010A Active JP6655618B2 (ja) | 2014-12-01 | 2015-12-01 | 安定な液体ワクシニアウイルス処方物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10517943B2 (enExample) |
| EP (1) | EP3226894B1 (enExample) |
| JP (1) | JP6655618B2 (enExample) |
| KR (1) | KR102507483B1 (enExample) |
| CN (1) | CN107206063B (enExample) |
| AU (1) | AU2015357225B2 (enExample) |
| DK (1) | DK3226894T3 (enExample) |
| ES (1) | ES2753364T3 (enExample) |
| IL (1) | IL252512B (enExample) |
| MX (1) | MX378901B (enExample) |
| RU (1) | RU2704485C2 (enExample) |
| WO (1) | WO2016087457A1 (enExample) |
| ZA (1) | ZA201703534B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3512939A1 (en) | 2016-09-16 | 2019-07-24 | Leukocare AG | A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy |
| WO2018050873A1 (en) | 2016-09-16 | 2018-03-22 | Leukocare Ag | A novel method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation |
| EP3624851A1 (en) | 2017-05-15 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| EP3624845A1 (en) | 2017-05-15 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| EP3762020A1 (en) | 2018-03-07 | 2021-01-13 | Transgene | Parapoxvirus vectors |
| US12150988B2 (en) | 2018-09-06 | 2024-11-26 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
| CA3124773A1 (en) | 2018-12-28 | 2020-07-02 | Transgene | M2-defective poxvirus |
| CN113646047B (zh) * | 2019-02-15 | 2025-07-08 | 印度血清研究所私人有限公司 | 减毒活流感疫苗组合物和用于制备其的方法 |
| PH12022550240A1 (en) * | 2019-08-29 | 2022-12-19 | Astellas Pharma Inc | Genetically engineered oncolytic vaccinia viruses and methods of uses thereof |
| CN110669739A (zh) * | 2019-09-30 | 2020-01-10 | 长春生物制品研究所有限责任公司 | 一种新型甲型肝炎病毒抗原制备方法 |
| EP3842065A1 (en) | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
| KR20220153587A (ko) | 2020-03-12 | 2022-11-18 | 버베리안 노딕 에이/에스 | 폭스바이러스 안정성을 개선하는 조성물 |
| WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
| CN115704011A (zh) * | 2021-08-11 | 2023-02-17 | 北京永泰生物制品有限公司 | 一种高稳定性的慢病毒制剂及其制备方法和其应用 |
| JP2025523573A (ja) | 2022-07-01 | 2025-07-23 | トランジェーヌ | サーファクタントタンパク質－ｄとｔｎｆｓｆのメンバーを含んでなる融合タンパク質 |
| EP4585699A1 (en) * | 2022-09-09 | 2025-07-16 | BGI Shenzhen | Use of heteroaromatic ring compounds in nucleic acid tests |
| CN117003897B (zh) * | 2023-08-10 | 2024-10-29 | 深圳泰华赛尔生物科技有限公司 | 靶向Claudin18.2的CAR-T细胞及其用途 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5255054Y2 (enExample) * | 1973-01-12 | 1977-12-13 | ||
| US3915794A (en) * | 1973-02-09 | 1975-10-28 | Rit Rech Ind Therapeut | Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| DK331087A (da) * | 1986-06-30 | 1987-12-31 | Smith Kline Rit | Stabilisator for levende vaccine |
| JPS6314729U (enExample) * | 1986-07-14 | 1988-01-30 | ||
| FR2643817B1 (fr) | 1989-03-06 | 1993-12-17 | Transgene Sa | Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| GB9001641D0 (en) | 1990-01-24 | 1990-03-21 | Imp Cancer Res Tech | Compounds |
| FR2668064B1 (fr) | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
| US6241989B1 (en) * | 1991-07-09 | 2001-06-05 | Cornell Research Foundation, Inc. | Recombinant multivalent viral vaccine |
| HU220080B (hu) * | 1992-06-04 | 2001-10-28 | Merck And Co. Inc. | Eljárás gyengített Varicella zoster vírus vakcina előállítására |
| FR2710536B1 (fr) | 1993-09-29 | 1995-12-22 | Transgene Sa | Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire. |
| FR2751879B1 (fr) | 1996-07-30 | 1998-10-30 | Transgene Sa | Composition pharmaceutique contre les tumeurs et infections a papillomavirus |
| US5672485A (en) | 1996-08-13 | 1997-09-30 | Regents Of The University Of Minnesota | Immortalized cell lines for virus growth |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| FR2777570A1 (fr) | 1998-04-17 | 1999-10-22 | Transgene Sa | Mutant ayant une activite phosphoribosyl transferase |
| US7456009B2 (en) | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| US7094412B2 (en) | 2001-12-10 | 2006-08-22 | Bavarian Nordic A/S | Poxvirus containing formulations and process for preparing stable poxvirus containing compositions |
| CN101804202B (zh) | 2003-02-25 | 2014-06-18 | 米迪缪尼有限公司 | 制备流感疫苗组合物的方法 |
| FR2855758B1 (fr) | 2003-06-05 | 2005-07-22 | Biomerieux Sa | Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique |
| US7790445B2 (en) | 2003-07-21 | 2010-09-07 | Transgene S.A. | Polypeptide having an improved cytosine deaminase activity |
| ATE467678T1 (de) | 2003-07-22 | 2010-05-15 | Vivalis | Produktion von poxviren mit adhärenten oder nicht adhärenten vogelzellinien |
| WO2005066333A1 (en) * | 2003-12-30 | 2005-07-21 | Aventis Pasteur, Inc. | Stabilizing compositions for recombinant viruses |
| MX2007005379A (es) | 2004-11-05 | 2007-07-04 | Wellstat Biologics Corp | Formulaciones de virus envueltos estables y filtrables. |
| KR101772375B1 (ko) | 2005-09-07 | 2017-08-29 | 신라젠(주) | Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법 |
| AU2007204024B2 (en) | 2006-01-05 | 2012-01-19 | Transgene S.A. | Avian telomerase reverse transcriptase |
| MX2008013489A (es) | 2006-04-21 | 2008-10-30 | Transgene Sa | Vacuna de virus de papiloma basado en hpv-18 (virus de papiloma humano 18). |
| DK2029756T3 (en) | 2006-06-20 | 2017-02-13 | Transgene Sa | PROCEDURE FOR PREPARING POXVIRA AND POXVIRUS COMPOSITIONS |
| KR20080084528A (ko) | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
| EP2176398B1 (en) | 2007-07-03 | 2016-12-28 | Transgene SA | Immortalized avian cell lines |
| AU2008328257B2 (en) | 2007-11-19 | 2013-08-22 | Transgene Sa | Poxviral oncolytic vectors |
| MX2010005273A (es) | 2007-11-19 | 2010-08-31 | Transgene Sa | Vectores oncoliticos poxvirales. |
| US7998488B2 (en) * | 2008-11-14 | 2011-08-16 | Baxter International Inc. | Vaccine formulations and uses thereof |
| BRPI1007744A2 (pt) * | 2009-05-12 | 2017-06-27 | Transgene Sa | método para a produção e purificação de um ortopoxvírus do tipo selvagem, ortopoxvírus do tipo selvagem, composição farmacêutica, uso de um ortopoxvírus do tipo selvagem e uso de uma linhagem de células aviárias imortalizadas |
| WO2014009433A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterium resuscitation promoting factor for use as adjuvant |
| TWI638829B (zh) | 2012-07-10 | 2018-10-21 | 法商傳斯堅公司 | 分枝桿菌抗原疫苗 |
| US9314519B2 (en) | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
| TWI690322B (zh) * | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
-
2015
- 2015-12-01 US US15/529,668 patent/US10517943B2/en active Active
- 2015-12-01 EP EP15804407.3A patent/EP3226894B1/en active Active
- 2015-12-01 ES ES15804407T patent/ES2753364T3/es active Active
- 2015-12-01 MX MX2017007178A patent/MX378901B/es unknown
- 2015-12-01 RU RU2017121019A patent/RU2704485C2/ru active
- 2015-12-01 KR KR1020177017299A patent/KR102507483B1/ko active Active
- 2015-12-01 AU AU2015357225A patent/AU2015357225B2/en active Active
- 2015-12-01 WO PCT/EP2015/078239 patent/WO2016087457A1/en not_active Ceased
- 2015-12-01 DK DK15804407.3T patent/DK3226894T3/da active
- 2015-12-01 JP JP2017529010A patent/JP6655618B2/ja active Active
- 2015-12-01 CN CN201580075166.2A patent/CN107206063B/zh active Active
-
2017
- 2017-05-23 ZA ZA201703534A patent/ZA201703534B/en unknown
- 2017-05-25 IL IL252512A patent/IL252512B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537910A5 (enExample) | ||
| ES2753364T3 (es) | Formulaciones líquidas estables de virus vaccinia | |
| CA2887156C (en) | Virus-containing formulation and use thereof | |
| CA2350890C (en) | Aqueous compositions for long-term stable storage of adenovirus particles including uses and methods for preparing same | |
| US10517910B2 (en) | Compositions and methods for viral embolization | |
| CN105530917B (zh) | 改进的腺病毒配制品 | |
| EP2420247A1 (en) | Adenovirus formulations | |
| JP2005513109A (ja) | ポックスウイルス含有調合物およびその調製方法 | |
| MX2019006353A (es) | Composiciones y metodos para evitar la agregacion del vector aav. | |
| JP7279086B2 (ja) | 強化された安定性を有するサルアデノウイルスベクターのための製剤 | |
| JP7712284B2 (ja) | ポックスウイルスの安定性を改善する組成物 | |
| WO2013177172A2 (en) | Herpesvirus compositions and related methods | |
| JP2004535203A5 (enExample) | ||
| HRP20220407T1 (hr) | Pripravci i postupci za uporabu u liječenju homocistinurije | |
| JP2020519677A (ja) | 安定なウイルス含有組成物 | |
| CA2969034C (en) | Stable liquid vaccinia virus formulations | |
| HK1242182A1 (en) | Stable liquid vaccinia virus formulations | |
| CA2990133C (en) | Compositions and methods for viral embolization | |
| HK1211206B (en) | Virus-containing formulation and use thereof | |
| HK40096275A (zh) | 免疫抑制的治疗 | |
| HK1226950B (en) | Improved adenovirus formulations | |
| OA17678A (en) | Improved adenovirus formulations. |